SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells.
Int J Mol Sci
; 21(16)2020 Aug 09.
Article
in English
| MEDLINE | ID: covidwho-713065
ABSTRACT
The pandemic evolution of SARS-CoV-2 infection is forcing the scientific community to unprecedented efforts to explore all possible approaches against COVID-19. In this context, targeting virus entry is a promising antiviral strategy for controlling viral infections. The main strategies pursued to inhibit the viral entry are considering both the virus and the host factors involved in the process. Primarily, direct-acting antivirals rely on inhibition of the interaction between ACE2 and the receptor binding domain (RBD) of the Spike (S) protein or targeting the more conserved heptad repeats (HRs), involved in the membrane fusion process. The inhibition of host TMPRSS2 and cathepsins B/L may represent a complementary strategy to be investigated. In this review, we discuss the development entry inhibitors targeting the S protein, as well as the most promising host targeting strategies involving TMPRSS2 and CatB/L, which have been exploited so far against CoVs and other related viruses.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Angiotensin-Converting Enzyme Inhibitors
/
Serine Proteinase Inhibitors
/
Virus Internalization
/
Betacoronavirus
Limits:
Animals
/
Humans
Language:
English
Year:
2020
Document Type:
Article
Affiliation country:
Ijms21165707
Similar
MEDLINE
...
LILACS
LIS